Moreover, the KRISTINE study revealed that higher expressions of both HER2 and immune markers within the tumor microenvironment correlated with higher pCR rates, suggesting that T-DM1 sensitivity might be linked to the activation of the anti-tumor immune response [20]. Here, ERBB2 is linked to neoplasm.